ASHTON JERKINS: Open Payments
NPI 1720495344 · MONTGOMERY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$457 in 23 payments from 14 companies in 2025. Trend: 2023 $445 · 2024 $688 · 2025 $457
Food & beverage: $457
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| Celgene Corporation | 3 | $55 |
| ABBVIE INC. | 3 | $51 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| BeiGene USA, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $20 |
| ARRAY BIOPHARMA INC | 1 | $20 |
Products named: LIBTAYO, REBLOZYL, EPKINLY, Fabhalta, XTANDI, BRUKINSA, SCEMBLIX, FRUZAQLA.
Industry payments across AL — which companies pay providers there.
